{"name":"Lineage Cell Therapeutics","slug":"lineage","ticker":"LCTX","exchange":"NYSE American","domain":"lineagecell.com","description":"Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.","hq":"Carlsbad, CA","founded":0,"employees":"72","ceo":"Brian M. Culley","sector":"Cell Therapy / Regenerative Medicine","stockPrice":1.33,"stockChange":0.05,"stockChangePercent":3.91,"marketCap":"$333M","metrics":{"revenue":14779000,"revenueGrowth":14.8,"grossMargin":-20.7,"rdSpend":17729000,"netIncome":-63533000,"cash":53381000,"dividendYield":0,"peRatio":-15.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AST-OPC1","genericName":"AST-OPC1","slug":"ast-opc1","indication":"Acute spinal cord injury","status":"phase_1"}]}],"pipeline":[{"name":"AST-OPC1","genericName":"AST-OPC1","slug":"ast-opc1","phase":"phase_1","mechanism":"AST-OPC1 is a human oligodendrocyte progenitor cell therapy that promotes myelination and repair in spinal cord injuries.","indications":["Acute spinal cord injury"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Lineage Cell Therapeutics reported its financial results for the fourth quarter and full year 2022, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Lineage Cell Therapeutics Announces $20 Million Private Placement","summary":"Lineage Cell Therapeutics announced a private placement of $20 million in a financing round.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"regulatory","headline":"FDA Grants Fast Track Designation to Lineage Cell Therapeutics' OpRegen for Dry Age-Related Macular Degeneration","summary":"The FDA granted fast track designation to Lineage Cell Therapeutics' OpRegen for the treatment of dry age-related macular degeneration.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPdDhFRzBhblBlWEVOem9NRFUtMmNQWVlvZjJyOVNtSjJ4al9tMGtkRERHT0Z2MFMxUmN4S0pCUjdISGR6ZGNCSWJCTnVsZDc3bFI4LWM4eXd4Q1ZkWjBNZkxrLUphVXI2eWtMdTNrZnpDdGpTandZRXJzYzdUMnc3SGJZYzlCZEpJTXRkQWJlNmVQTk9iZTI1SVd6aW1HWU00RE5pc3RwZGhDN2dpUHU3RmtqZnJoSnpYZDRCUFBUbWtnQUZ6bVV4eUtuNjU3RW9OODJFLU4zNlJMZ2F3bDA0cDlzekVsTHBy?oc=5","date":"2026-04-06","type":"trial","source":"The Globe and Mail","summary":"Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - The Globe and Mail","headline":"Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBab3lCblFPdlF5STNNa2dsQnh5N2VhUERuVUFlbU5XbHdWckt3MjNJTU84T3BoREptVnFyRUJhNngzUm5UQTdXUGIzaUZCeldGMWxCRU90NzFuUQ?oc=5","date":"2026-04-06","type":"trial","source":"Lelezard","summary":"Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Lelezard","headline":"Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOaUc2OWpjM2NEVlcwMEJPamhCOEF0M3BreFAxakQ5Q1pRRGRZNjhrRnk0V2VyNG4yWWJ4YURBZWY4djJVZkNLV3RPeURNdU1BLUM0TGhMYmoyUU12MTZlSFlXYXBxclRiOEVlT3Fhbl9tdFktTFgtOFlvQnY5UnFfM2pseEl3NWZnYk1jMW5WVTFQeXFHb0ZQMUtpbmJnM3F3Y0tBazVtU1ZxeDRUckd4VjBrb2U5NEh5dkZKWDZGUjV4N3ZETG9zLWZieUhYTG84ZkZEYmZGYTVXZw?oc=5","date":"2026-01-29","type":"pipeline","source":"PR Newswire","summary":"Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - PR Newswire","headline":"Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration","sentiment":"neutral"},{"date":"2025-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNLXJTdkFmMmlHSTgzM0J3NEpGUVpBUGlkeTNtQzV0T3NCdmZyUlpINmhZTWFrUTQyQ05KbmtLX0RNdUVMdHBiRldISHFXUzIyMVBCaDhRaVllLVBsbzBLb2w3NUFtSDlDWDZpcm1saER5ZjI2dlZvNHRuS053X3pJUmNrVmNqNTMxYUVIZGZkRmkzMUhLdldIZg?oc=5","date":"2025-09-08","type":"regulatory","source":"San Diego Business Journal","summary":"Lineage Nabs $12M Demant Partnership - San Diego Business Journal","headline":"Lineage Nabs $12M Demant Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQbTJDRlNvZy1qdjE0VFdla094OWhqVDZDaUNuZmE0U3U4Z19UdXBMMFJHMGM5U1g0VC1ndTVnVlBkODVvb2RPNnh2LUFabmJhalY4X1huSElERHk2cm00TngtQ3RaMkp0MnhTX3I5Z3lOU1drMHhoWGE1d2RxNjNlRVVDRGo4QWFnWXZHa3hnb1FwRFRqeVdJM2d3WXJ6M0RWVEt2LURQMVZCVjlNNzVXUmpR?oc=5","date":"2025-01-06","type":"pipeline","source":"Business Wire","summary":"Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire","headline":"Lineage Cell Therapeutics Issues Letter to Stockholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNFBTYUE1Y0M4cVJlbVp3TGVQdnlRbVhabG9jOFRMejYxc0ZYQmFBNXRCVzdUQTB1MDM1d3hzUTUzQlhzNGxwaXZ2ZnhYNExhOU80X3FsazAwTnpUekJzcHQzNHl2V05QWDdRQ2dNeTdmRmx5elhUbHhWM1AtdmxraGFJcmxOZHZfWXpBcWdKMFdVWXFPcVVydnNScWMwcHZNTDBCcFJB?oc=5","date":"2024-01-15","type":"pipeline","source":"Seeking Alpha","summary":"Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company (NYSE:LCTX) - Seeking Alpha","headline":"Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company (NYSE:LCTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcE8tc25QcU91OEJfVUg3WWQ4RmdLakNjdUZVVjVXaThzMjRkLUgxZzdDU3FmT1ZZNzlaRkp2N2Rmb0RoNFdMNlk1ODNfb2U3bUZfdVlsQUFtdkc5MzhWektJc2dxYTBRdGUtUnJ3cnNzWE9qN25PQWFzVzZFdXpaN3V5dEhiS0lHUVhaMzZFd2RvQktWOEVqb29zeG5rQld2UmQ2R1hNSE1WS0ZXZUlXa3ZIdTYxM2RUd1V3S3hHaGhTcDk0ZWY2Mw?oc=5","date":"2021-12-20","type":"pipeline","source":"Fierce Biotech","summary":"Roche adds to Genentech's ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics' asset - Fierce Biotech","headline":"Roche adds to Genentech's ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics' asset","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Athersys","Mesoblast","Pluristem"],"therapeuticFocus":["Ophthalmology","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":14556000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":14556000,"period":"2025-12-31"},{"value":9499000,"period":"2024-12-31"},{"value":9499000,"period":"2024-12-31"},{"value":8945000,"period":"2023-12-31"},{"value":8945000,"period":"2023-12-31"}],"grossProfit":14410000,"grossProfitHistory":[{"period":"2025-12-31","value":14410000},{"period":"2024-12-31","value":9165000},{"period":"2023-12-31","value":8274000},{"period":"2022-12-31","value":13975000}],"rdSpend":17729000,"rdSpendHistory":[{"period":"2025-12-31","value":17729000},{"period":"2024-12-31","value":12472000},{"period":"2023-12-31","value":15705000},{"period":"2022-12-31","value":13987000}],"sgaSpend":18460000,"operatingIncome":-21779000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-21779000},{"period":"2024-12-31","value":-21478000},{"period":"2023-12-31","value":-24733000},{"period":"2022-12-31","value":-22520000}],"netIncome":-63533000,"netIncomeHistory":[{"period":"2025-12-31","value":-63533000},{"period":"2024-12-31","value":-18609000},{"period":"2023-12-31","value":-21486000},{"period":"2022-12-31","value":-26273000}],"eps":-0.28,"epsHistory":[{"period":"2025-12-31","value":-0.28},{"period":"2024-12-31","value":-0.09},{"period":"2023-12-31","value":-0.12},{"period":"2022-12-31","value":-0.15}],"cash":40791000,"cashHistory":[{"period":"2025-12-31","value":40791000},{"period":"2024-12-31","value":45789000},{"period":"2023-12-31","value":35442000},{"period":"2022-12-31","value":11355000}],"totalAssets":112584000,"totalLiabilities":69238000,"totalDebt":2419000,"equity":44549000,"operatingCashflow":-18919000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-18919000},{"period":"2024-12-31","value":-23092000},{"period":"2023-12-31","value":-28566000},{"period":"2022-12-31","value":1059000}],"capex":-522000,"capexHistory":[{"period":"2025-12-31","value":-522000},{"period":"2024-12-31","value":-565000},{"period":"2023-12-31","value":-674000},{"period":"2022-12-31","value":-413000}],"freeCashflow":-19441000,"dividendsPaid":null,"buybacks":-16000,"employees":72,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4852000,"ebit":-6548000,"ebitda":-6362000,"period":"2025-12-31","revenue":6608000,"epsBasic":null,"netIncome":851000,"rdExpense":8238000,"epsDiluted":null,"grossProfit":6542000,"operatingIncome":-6548000},{"sga":4191000,"ebit":-3786000,"ebitda":-3608000,"period":"2025-09-30","revenue":3681000,"epsBasic":-0.13,"netIncome":-29781000,"rdExpense":3271000,"epsDiluted":-0.13,"grossProfit":3676000,"operatingIncome":-3786000},{"sga":4560000,"ebit":-4940000,"ebitda":-4769000,"period":"2025-06-30","revenue":2765000,"epsBasic":-0.13,"netIncome":-30464000,"rdExpense":3106000,"epsDiluted":-0.13,"grossProfit":2726000,"operatingIncome":-4940000},{"sga":4857000,"ebit":-6505000,"ebitda":-6341000,"period":"2025-03-31","revenue":1502000,"epsBasic":-0.02,"netIncome":-4139000,"rdExpense":3114000,"epsDiluted":-0.02,"grossProfit":1466000,"operatingIncome":-6505000},{"sga":4401000,"ebit":-5110000,"ebitda":-4959000,"period":"2024-12-31","revenue":2868000,"epsBasic":null,"netIncome":-3273000,"rdExpense":3423000,"epsDiluted":null,"grossProfit":2714000,"operatingIncome":-5110000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.02,"netIncome":null,"rdExpense":null,"epsDiluted":-0.02,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.33,"previousClose":1.28,"fiftyTwoWeekHigh":2.09,"fiftyTwoWeekLow":0.45,"fiftyTwoWeekRange":"0.45 - 2.09","fiftyDayAverage":1.56,"twoHundredDayAverage":1.58,"beta":0,"enterpriseValue":266934816,"forwardPE":-15.1,"priceToBook":6.18,"priceToSales":22.52,"enterpriseToRevenue":18.06,"enterpriseToEbitda":-12.05,"pegRatio":0,"ebitda":-22144000,"ebitdaMargin":-149.8,"freeCashflow":-14626875,"operatingCashflow":-22111000,"totalDebt":2394000,"debtToEquity":4.5,"currentRatio":6.89,"returnOnAssets":-12.9,"returnOnEquity":-98.2,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":5.14,"targetHighPrice":9,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.9,"institutionHeldPercent":44,"sharesOutstanding":249298295,"floatShares":187280358,"sharesShort":25584679,"shortRatio":23.42,"shortPercentOfFloat":10.3,"epsTrailing":-0.29,"epsForward":-0.09,"revenuePerShare":0.06,"bookValue":0.22,"officers":[{"age":54,"name":"Mr. Brian M. Culley M.A., M.B.A.","title":"CEO, President & Director"},{"age":49,"name":"Ms. Jill Ann Howe","title":"Chief Financial Officer"},{"age":44,"name":"Mr. George A. Samuel III, J.D.","title":"General Counsel & Company Secretary"},{"age":null,"name":"Ms. Ioana C. Hone","title":"Director of Investor Relations"},{"age":null,"name":"Dr. Charlotte  Hubbert Ph.D.","title":"Vice President of Corporate Strategy & Development"},{"age":null,"name":"Dr. Priyantha  Herath M.D., Ph.D.","title":"Senior VP & Head of Clinical Operations"},{"age":67,"name":"Dr. Rami  Skaliter M.Sc., Ph.D.","title":"Chief Executive Officer of Cell Cure Neurosciences"},{"age":null,"name":"Ms. Alexandra  Hernandez","title":"Senior Director of Finance & Controller"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.lineagecell.com","phone":"442 287 8990"}}